Immunic Inc (IMUX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.11+2.74%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMUX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 90.6 | 82.0 | 80.0 | 83.2 | 71.3 | 61.1 | 38.6 | 22.5 | 9.6 | 39.3 | 30.0 | 39.8 | 39.5 |
| Operating Income | (117.9) | (103.2) | (98.1) | (99.2) | (119.5) | (91.7) | (49.0) | (37.0) | (12.0) | (52.7) | (41.3) | (52.1) | (50.3) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | 0.4 |
| Interest & Investment Income | 2.7 | 1.0 | 3.4 | 3.1 | 1.0 | 0.1 | 0.1 | 0.1 | 0.5 | 0.7 | 0.3 | 0.1 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | 0.4 |
| Other Non-Operating Income / Expenses | 6.3 | 6.1 | (2.5) | 5.6 | (0.9) | (1.3) | 5.0 | 2.1 | 0.5 | 0.6 | 0.3 | 0.1 | 2.7 |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | (41.5) | (52.1) | (41.0) | (52.0) | (47.7) |
| Net Income | |||||||||||||
| Net Income | (111.6) | (97.2) | (100.5) | (93.6) | (120.4) | (92.9) | (44.0) | (34.9) | (11.5) | (52.1) | (41.0) | (52.0) | (47.7) |
| Per Share | |||||||||||||
| Basic EPS | (2.62) | (0.62) | (1.00) | (2.11) | (3.78) | (3.93) | (2.81) | — | — | — | — | — | — |
| Diluted EPS | (2.62) | (0.62) | (1.00) | (2.11) | (3.78) | (3.93) | (2.81) | — | — | — | — | — | — |
| Dividend per Share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Basic Weighted Avg Shares | 42.5 | 155.7 | 100.2 | 44.3 | 31.8 | 23.7 | 15.7 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 42.5 | 155.7 | 100.2 | 44.3 | 31.8 | 23.7 | 15.7 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (103.1) | (97.9) | (99.1) | (119.4) | (91.6) | (48.9) | (37.0) | (12.0) | (51.7) | (39.5) | (50.8) | (49.2) |
| EBIT | (117.9) | (103.2) | (98.1) | (99.2) | (119.5) | (91.7) | (49.0) | (37.0) | (12.0) | (52.7) | (41.3) | (52.1) | (50.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.